See the DrugPatentWatch profile for semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a medication used to treat type 2 diabetes. The patent for semaglutide, marketed as Ozempic and Wegovy, is owned by Novo Nordisk, a Danish pharmaceutical company.

According to DrugPatentWatch.com, a reliable source for tracking pharmaceutical patents, the patent for semaglutide was filed on October 22, 2007, and was granted on June 22, 2010 [1]. The patent is set to expire on June 22, 2030 [1].

It's worth noting that patent expiration dates can be complex and may involve multiple patents with different expiration dates. In the case of semaglutide, the patent expiration date mentioned above refers to the original patent filing. However, it's possible that subsequent patents or patent extensions may have been filed, which could affect the actual patent expiration date.

In summary, the precise date of semaglutide's patent expiration is June 22, 2030, according to DrugPatentWatch.com.

Sources:

[1] DrugPatentWatch.com. (n.d.). Semaglutide (Ozempic, Wegovy). Retrieved from <https://www.drugpatentwatch.com/patent/US-2010-0164446>

Note: The patent expiration date mentioned above is subject to change and may not reflect any subsequent patent extensions or changes.